Although bioethics consultation has always drawn the ire of critics,1
Scofield GR. Ethics consultation: The least dangerous profession? Cambridge Quarterly of Healthcare Ethics 1993;2(4):417–26.
Turner L. The greening of bioethics: Corporate funding of bioethics research. Cambridge Quarterly of Healthcare Ethics 1998;7(3):326–8; Elliott C. Pharma buys a conscience. American Prospect 2001;12(17):16–20; Stolberg SG. Bioethicists find themselves the ones being scrutinized. New York Times 2001 Aug 2:A1; Turner L. Bioethic$ Inc. Nature Biotechnology 2004;22(8):947–8; DeVries R. Businesses are buying the ethics they want. Washington Post 2004 Feb 8:B2; Elliott C. The soul of a new machine: Bioethicists in the bureaucracy. Cambridge Quarterly of Healthcare Ethics 2005;14(4):379–84.
See note 2, Elliott 2001.
See note 2, Turner 2004.
Brody B, Dubler N, Blustein J, Caplan A, Kahn JP, Kass N, et al. Bioethics consultation in the private sector. The Hastings Center Report 2002;32(3):14–20.
Sharpe VA. Science, bioethics, and the public interest: On the need for transparency. Hastings Center Report 2002;32(3):23–6; Youngner SJ, Arnold R. Who will watch the watchers? The Hastings Center Report 2002;32(3):21–2.
Baker R. A draft model aggregated code of ethics for bioethicists. American Journal of Bioethics 2005;5(5):33–41; MacDonald C. Will the “secular priests” of bioethics work among the sinners? The American Journal of Bioethics 2003;3(2):W36–9; Parsi K. Bioethics consultation in the private sector: What is an appropriate model. HEC Forum 2005;17(2):135–45.
As central to debates about professional roles in bioethics as this controversy about industry relationships has been, discussions of competing interests in bioethics consultation should not be limited to this setting alone. There are many contexts in which a consultant's professional activities might be compromised by competing interests and obligations. Many clinical ethicists, for example, are compensated by hospitals for the provision of in-house consultation services.8
See note 7, Parsi 2005:137.
See note 2, Elliott 2001.
We examine one context in which competing interests in bioethics consultation have received little attention to date, namely, in consulting relationships with patient advocacy organizations. Drawing upon our experiences with one such organization, we examine competing interests and threats to professional objectivity that may arise in this setting. We argue that, over time, a consultant's objectivity can be eroded in this context due to the confluence of personal, professional, and patient goals associated with such consulting activities. Although these consulting relationships may not generate as much controversy as consultant relationships with industry, it nevertheless is important that bioethicists recognize and responsibly manage competing interests in this setting. We also believe examining the nature of potential threats to professional objectivity in consultant relationships with patient advocacy organizations will prove to be fertile ground for broader reflections on the scope and nature of appropriate professional activities in bioethics.
An Evolving Relationship with Patient Advocacy
For the past 8 years we have served as volunteers to the Alpha-1 Foundation (hereafter, the Foundation), a nonprofit patient advocacy organization that seeks to promote research on Alpha-1 Antitrypsin Deficiency (Alpha-1). Alpha-1 is a monogenetic condition associated with potentially fatal lung and liver disease.10
Alpha1-Antitrypsin Deficiency Task Force. American Thoracic Society/European Respiratory Society Statement. Standards for the Diagnosis and Management of Individuals with Alpha1-Antitrypsin (AAT) Deficiency. American Journal of Respiratory and Critical Care Medicine 2003;168:818–900.
See note 10, Alpha1-Antitrypsin Deficiency Task Force 2003.
We began working with the Foundation when we were asked to help develop a consensus statement on Alpha-1 screening and detection, a document that was prepared in conjunction with the American Thoracic Society and the European Respiratory Society.12
See note 10, Alpha1-Antitrypsin Deficiency Task Force 2003.
Sharp RR, de Serres F, Newman L, Sandhaus RA, Walsh JW, Hood E, Harry GJ. Environmental, occupational, and genetic risk factors for alpha-1 antitrypsin deficiency. Environmental Health Perspectives 2003;111:1749–52. We have never accepted any honoraria or consultant fees for our work with the Foundation. However, we are reimbursed for our travel, lodging, meals, and other incidental expenses associated with work on its behalf. In addition, we each have received $25,000 research grants from the Foundation. One of the ethics centers with which one of us is affiliated also received $2,500 from the Foundation to support a conference on ethics and genetics.
We believe our work with the Foundation has been mutually beneficial on several levels. We have seen members of the Foundation become increasingly sophisticated with regard to their understanding of ethical issues related to Alpha-1—and more attendant to the manner in which the Foundation might contribute to the management of those issues. We also have seen members of the Foundation promote the contributions of the ELSI Working Group and note its uniqueness among patient advocacy organizations.14
Beyond Science. Alpha-1-to-One; Fall 2003:10–1.
On a personal level, neither of our family histories suggests a risk of Alpha-1 and thus, in an important way, we remain outsiders to the Alpha-1 community. Through our work with the Foundation, however, we have had the privilege of meeting many people with Alpha-1 whom we greatly admire and regard as dear friends. We have celebrated their accomplishments and wept alongside them in remembrance of those persons whose lives have been cut short by this devastating disease. Although it was professional interest, not personal concern, that was the genesis of our relationship with the Foundation, our continuing commitment to working with the Foundation is no doubt strengthened by these personal relationships.
Professional Objectivity and Personal Allegiances
Although bioethics consultation with patient advocacy organizations may involve many of the same activities as analogous relationships with industry, several features of consultation with patient organizations suggest different threats to professional objectivity. For example, unlike bioethics consultation with industry, consultation with patient advocacy organizations often is motivated by shared commitments to advance the interests of persons with chronic health problems. In addition, bioethics consultation with patient advocacy organizations, unlike typical consultation with industry, frequently takes place over an extended period of time and may involve a range of activities. We explore how these differences may mask competing interests and thus make it more difficult to appreciate potential threats to professional objectivity in work with patient advocacy organizations.
Shared Values and Goals
The frequent lack of financial remuneration for the provision of consultation services to patient advocacy organizations suggests that bioethicists engaged in these activities often do so because of the coalescence between their personal values, their professional goals, and the aims and objectives of the organizations seeking bioethics consultation. Such coalescence is not bad. To the contrary, it can inspire one to do one's best work. At the same time, however, deeply shared values may prompt passionate responses or judgments shaped in part by enthusiasm for patient concerns. Consultants must recognize the danger posed by the inspiration generated from work with patient organizations and remind themselves of the need to render objective, professionally sound advice based on critical thought and analysis. Preserving this ability is key because a consultant may be speaking from a position informed by personal passion, reaffirming the orienting values of the nonprofit organization, but is simultaneously being heard as a professional with all the authority attached to that role.
In our work with the Foundation, there have been times when we have struggled with these issues, as we have come to appreciate the many ways in which our own personal and professional values overlap with those of the Foundation. We have come to believe, for example, that the Foundation is pursing important social goals, chief among them improvement in the care of persons affected by Alpha-1 and more enlightened public policy regarding ethical, legal, and social issues pertinent to patients with genetic conditions. We have been pleased to have had the opportunity to provide professional services to the Foundation in their pursuit of these goals. In addition, through this work, we increasingly have come to identify with the interests of the Alpha-1 community ourselves in a far richer way than would have been possible had we not developed these relationships. Moreover, the coalescence of the Foundation's work with our own is not limited to mere identification with their priorities. It is far more reciprocal. Over time, we have begun to give more back to the organization, both in terms of personal time and professional commitments.
If bioethicists are to protect their capacity to render unbiased professional assessments of issues directly affecting the interests of organizational sponsors, however, they cannot allow the passionate pursuit of shared goals to undermine the voicing of criticism when appropriate. We confronted this challenge several years ago when the Foundation announced plans to launch an ambitious national screening initiative to identify persons affected by Alpha-1. We had a number of concerns about the potential risks and costs of this initiative. We voiced these concerns, but, in hindsight we suspect our criticisms were more muted than they might otherwise have been had we not felt such a strong allegiance with the Foundation. We also have, at times, wished for greater transparency regarding the organization's ties to private industry but have not pursued this matter as aggressively as we might have in other settings.
The more a consulting bioethicist identifies with the mission of an organization, the more personal interest there may be in protecting the future of that relationship. We are not referring to financial or other direct personal rewards that can exist in any consulting relationship. Instead, we have in mind the desire to maintain a seat at the table if a consultant strongly identifies with the advocacy organization's mission and wishes to continue to help shape the organization's pursuit of what the consultant regards as a noble set of social goals. Depending on the strength of this desire to continue the relationship and not to lose influence in the pursuit of what is regarded as an important cause, a consultant's professional judgment or willingness to advocate positions that the consultant knows will be unpopular may be compromised. Additionally, this desire can make it difficult to critically assess situations in which it may be appropriate to end the relationship altogether. Unlike consulting for industry clients, where one often merely works for a client, either in the absence of a strong identification with organizational goals or with a disjuncture between corporate or bioethical goals,15
DeVries RG, Bosk CL. The bioethics of business: Rethinking the relationship between bioethics consultants and corporate clients. The Hastings Center Report 2004;34(5):28–32.
Extended Multifaceted Relationships
We suspect many consultant relationships with nonprofit organizations take place over extended periods. It is natural, and even desirable, that in these circumstances consultants develop close personal relationships with particular individuals within the organization. As a result, unlike relationships with industry that may be task or time specific and sustained principally by financial remuneration, consultant relationships with patient advocacy organizations often are more akin to friendships than contractual arrangements. Accordingly, bioethics consultants must be mindful of the possibility that their work may be influenced, perhaps in very subtle ways, by a desire to meet the personal needs of individuals they have met through patient advocacy organizations.
To illustrate this possibility, consider another example from our work with the Foundation. As members of the Foundation's ELSI Working Group, we were consulted about proposed revisions to United Network for Organ Sharing (UNOS) policies for allocating lungs for transplant. After reviewing these proposed revisions and considering their potential impact on persons with Alpha-1, we tentatively concluded that, although the revised policies might result in fewer Alpha-1 patients receiving lung transplants, the policy revisions had been developed through a deliberative process that we believed could withstand moral scrutiny. Based on this assessment, we were reluctant to accept the Foundation's request to provide a more detailed analysis of the issues of social justice at stake in this debate. Our conflict stemmed from the fact that, despite our commitment to helping advance the needs of the Alpha-1 community, we believed the moral defense of the status quo that some in the Alpha-1 community were hoping to mount would be unpersuasive (and perhaps unfair to patients with other chronic health problems). As such, we did not believe we could in good faith provide our assistance. However, we recognized the emotional interests at stake and the need for some level of support. We did not want our saying “no” to a particular request from close associates to help muster a critique of the proposed UNOS criteria to also be heard as “no, we are not sensitive to your concerns regarding the significance of the underlying issue and its possible ramifications to persons with Alpha-1.”
The closer a consultant's personal ties to leaders of the organization, the greater the potential threat to his or her ability to act in an objective manner in circumstances such as this. To the extent that one is mindful of the emotional and personal needs of one's clients, who also may be regarded as close friends, one may feel an obligation to be responsive to those needs. Thus, the multifaceted relationships that arise in this setting may cause the consultant to be more responsive to the person soliciting bioethics advice than the relevant issues at stake. Where strong organizational leadership exists, there may be additional ambiguities about whether the consultant is advising the organization, specific organizational leaders, or the patients the organization purports to represent, ambiguities that can be exacerbated by the lack of contractual agreements defining the scope of consultation services.
Although bioethics consultants may become friends with clients from industry, we suspect such friendships are not fostered to the same extent by a shared commitment to the organization's mission. When a consultant works for a client according to terms set forth in a contract, as often occurs in work with private industry, the consultant typically completes a clearly defined task and thereby brings the relationship to a close. In work with patient advocacy organizations, where a consultant is more likely to work with organizational leaders on a variety of tasks in the pursuit of shared goals, in contrast, a consultant might reasonably believe these individuals (and the patient community they represent) have a moral claim on him or her that transcends any specific task.
Recommendations
The foregoing considerations highlight how consulting with patient advocacy organizations can create competing interests and pose threats to professional objectivity not typically found in work with industry clients. Based on our experiences working with one such organization, we offer the following practical recommendations to others interested in working with patient advocacy organizations:16
The following recommendations were developed by the authors independently from other extant recommendations, but readers will note similarities between some of our recommendations and those found in the ASBH/SLME Task Force (see note 5, Brody 2002).
- Establish mutual transparency about the multiple personal and professional motivations for entering into and continuing such a relationship.
- Prior to the commencement of consulting services, affirm that the consultant has the ability to exercise professional discretion and independence at all times so there is no presumption of a “predetermined” outcome for one's work.
- Preserve the ability to help advance the field by publicly reporting on the nature of one's consulting activities, for example, in academic publications or conference presentations, just as bioethicists do in other areas of public service and consulting.
- Consider avoiding relationships altogether if they place significant restrictions on one's ability to share aspects of the work with colleagues in bioethics.
- Establish time and other limits to the voluntary services one can provide; acknowledging these at the outset clarifies that an inability to provide some services may be due to competing time commitments and should not be construed as diminishing personal commitment.
- Consider whether direct compensation would be useful in setting boundaries, establishing accountability, and clarifying expectations regarding the scope of mutual commitments.
- Establish with sponsor organizations in advance a process for ending a relationship or bringing in additional expertise when one lacks the objectivity to address specific issues that will not be detrimental to either party in the event that substantive and irresolvable differences arise.
- Take time to learn about the individual advocacy organization, its mission and goals, and other organizations providing support to patients with the relevant disorder.
- Consider participating as an expert volunteer with a nonprofit organization; it can be both personally and professionally rewarding and is not unlike activities such as clinical rounds that allow bioethicists to gain a fuller appreciation of the multiple moral dimensions of healthcare.
We offer these recommendations in the hope that they will spur additional discussion about bioethics consultation with patient advocacy organizations. Such discussion can help highlight the potential threats to professional objectivity that may occur when personal interests and organizational goals become blurred.
Conclusion
We think controversy about bioethics consulting reflects both the maturity of the field and the fact that it has reached a precarious time. That is why we believe it is important to focus on more than just bioethicists' relationships with private industry. However, to date, the many other contexts in which bioethicists' professional activities might be compromised, or might be perceived as compromised, by nonfinancial conflicts of interest and obligation have been largely overlooked. Because relatively few bioethicists consult directly with private industry, there also can be an individual tendency by those not engaged in such work to believe they are immune to potential threats to professional objectivity in their own work with other organizations when, if our analysis is correct, they likely are not.
The issues we have drawn attention to should not leave readers with a sense, however, that we are skeptical about the value of working with patient advocacy organizations. Bioethicists can make important contributions to such organizations. Equally important, they have much to learn from these organizations and the issues they face.17
Dresser R. When Science Offers Salvation: Patient Advocacy and Research Ethics. New York: Oxford University Press; 2001.
